Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J. Meuleman P, et al. Among authors: vercauteren k. Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67. doi: 10.1128/AAC.00633-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896910 Free PMC article.
HCV animal models and liver disease.
Vercauteren K, de Jong YP, Meuleman P. Vercauteren K, et al. J Hepatol. 2014 Nov;61(1 Suppl):S26-33. doi: 10.1016/j.jhep.2014.07.013. Epub 2014 Nov 3. J Hepatol. 2014. PMID: 25443343 Free article. Review.
Animal models for the study of HCV.
Vercauteren K, de Jong YP, Meuleman P. Vercauteren K, et al. Curr Opin Virol. 2015 Aug;13:67-74. doi: 10.1016/j.coviro.2015.04.009. Epub 2015 May 23. Curr Opin Virol. 2015. PMID: 26304554 Free PMC article. Review.
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P. Vercauteren K, et al. Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045. Epub 2015 Aug 25. Gut. 2016. PMID: 26306759
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. Desombere I, et al. Among authors: vercauteren k. Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23. Antiviral Res. 2017. PMID: 29074219 Free PMC article.
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Vercauteren K, et al. Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30. Hepatology. 2014. PMID: 24797654 Free PMC article.
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ. Khera T, et al. Among authors: vercauteren k. Antiviral Res. 2017 Mar;139:129-137. doi: 10.1016/j.antiviral.2017.01.001. Epub 2017 Jan 3. Antiviral Res. 2017. PMID: 28062191 Free PMC article.
168 results